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Abstract
Purpose: EGF-stimulated signaling via EGF receptor (EGFR) is important in colorectal tumorigenesis and
drug targeting. However, anti-EGFR therapy is not effective in a subset of patients with colorectal cancer,
suggesting that unidentified EGF-stimulated pathways might play roles in colorectal cancer. Previously, we
identified KAI1 C-terminal interacting tetraspanin (KITENIN) as a metastasis-enhancing gene and found it
to be highly expressed in sporadic colorectal cancer tissues. We recently found that EGF further increases
KITENIN-induced elevated AP-1 activity. Here we attempted to clarify this novel EGF-stimulated molecular
pathway and its roles in colorectal cancer.
Experimental Design: We analyzed how EGF modulates the downstream signaling pathway of
oncogenic KITENIN in colorectal cancer cells. Biological alterations following EGF treatmentwere identified
in KITENIN-overexpressed colorectal cancer cells with or without alteration of EGFR activity.
Results:We identified the KITENIN/ErbB4–Dvl2–c-Jun axis as a novel downstream signal of EGF that is
switched on under elevated KITENIN conditions in an EGFR-independent manner. This unconventional
EGF signal upregulates c-Jun and enhances invasion and anchorage-independent growth of colorectal
cancer cells. In addition, tumor tissues from metastatic patients with colorectal cancer who showed initial
poor responses to cetuximab/chemotherapy expressed higher levels of KITENIN than did responders to
therapy.
Conclusions: Our results highlight the role of an EGFR-independent EGF signal in mediating the
invasiveness and tumorigenesis of colorectal cancer cells. This unconventional pathway might be related to
the limited clinical efficacy of anti-EGFR agents in a subset of patients with colorectal cancer.ClinCancer Res;
20(15); 4115–28. 2014 AACR.
Introduction
EGF is released through paracrine signaling from the
tumor-associated microenvironment and is critical in the
facilitationofmetastasis. The EGF receptor (EGFR, ErbB1) is
the cell-surface receptor formembers of the EGF family, and
the ErbB family includes 4different tyrosine kinases (ErbB1,
ErbB2, ErbB3, ErbB4) that are activated following binding
to ErbB ligands. The ErbB tyrosine kinasesmediate complex
interactions between tumor cells and their microenviron-
ment that may ultimately result in enhanced tumor pro-
gression, which thus makes ErbB an interesting target for
therapeutic intervention in several human cancers (1, 2).
Although EGFR is overexpressed in colorectal cancer tissues,
EGFR kinase inhibitors with proven efficacy in other clinical
settings often fail to block metastatic recurrence of colorec-
tal cancer (3, 4). One reason for this lack of response is the
heterogeneity of colorectal cancers. In previous studies,
colorectal cancers lacking oncogenic alterations in KRAS,
BRAF, PIK3CA, and PTEN genes (so-called "quadruple
negative" tumors) were shown to have the highest proba-
bility of a response to anti-EGFR therapy (5, 6). However,
approximately 20% of patients with metastatic colorectal
cancer who show no response to anti-EGFR targeted ther-
apies do not harbormutations in KRAS, BRAF, and PIK3CA,
nor loss of PTEN expression (7).
Such poor responses in these patients with colorectal
cancer have led investigators to seek a broader understand-
ing of kinase-independent EGFR functions that might sup-
port tumor growth. In one such study, EGFRwas reported to
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maintain the basal intracellular glucose level independent
of its kinase activity and thereby to prevent cells from
undergoing autophagic death, leading to increased tumor
cell survival, even in the presence of EGFR kinase inhibitors
(8). Accordingly, delineation of novel downstream signals
of EGF that do not involve EGFR is of tremendous impor-
tance, because such signals endow colorectal cancer cells
with prosurvival responses to anti-EGFR therapies, never-
theless, these signals have not yet been identified.
Previously, we identified KAI1 C-terminal interacting
tetraspanin (KITENIN) as a metastasis-enhancing gene
(9, 10) that participates in the dissemination of colorectal
(11, 12), squamous (13–15), gastric (16), and hepatocel-
lular cancer cells (17). KITENIN protein expression is sig-
nificantly higher in human colon (11, 12), laryngeal (14),
oral cavity squamous (15), gastric (16), and hepatocellular
(17) cancer tissues than in corresponding normal mucosa
or early-stage cancer tissues. Interaction of KITENIN
with Dishevelled (Dvl)/PKCd is important in regulating
colorectal cancer cell invasion via ERK/AP-1 activation
(11) and expression of KITENIN is significantly associated
with lymph node metastasis and poor survival of colorectal
cancer (12).However, it is unknownhowelevatedKITENIN
drives colorectal cancer progression and whether extracel-
lular signals, such as EGF or HGF, from the tumor-asso-
ciated microenvironment modulate the downstream
signaling pathway of oncogenic KITENIN to contribute to
colorectal tumorigenesis.
In this study, we investigated how extracellular signals
affect elevated KITENIN-induced increases in colorectal
cancer cell invasiveness and whether the action of extracel-
lular signals on KITENIN, such as EGF, is involved in the
failure of anti-EGFR therapies in patients with metastatic
colorectal cancer. We identified a novel EGFR-independent
oncogenic signal of EGF that works under coexpressed
KITENIN and ErbB4. Our present results indicate that an
alternative signaling pathway of EGF stimulates the forma-
tion of a functional complex among membrane-associated
scaffolding proteins, KITENIN/ErbB4, which are not cog-
nate receptors of EGF. This unconventional EGF signal may
cause a decrease in the sensitivity to treatment with anti-
EGFR agents in patients with cancer.
Materials and Methods
Plasmids and cell lines
Expression constructs ofHA-orV5-taggedKITENIN,GST-
tagged KITENIN deletion mutants, HA-tagged ErbB4 dele-
tionmutants, EGFR,HA-taggedDvl2,DN-c-jun, andNrdp1
were generated by PCR-based methods. All constructs were
confirmedby sequencing. ErbB4 cDNAwas kindly provided
by K. Elenius (University of Turku, Finland). Human colo-
rectal cancer cell lines (Caco2, DLD-1, HCT116, HT29, SW-
480, and SW-620), Chinese hamster ovary (CHO)-K1 cells,
and human embryonic kidney (293 T) cells were obtained
from American Type Culture Collection and were grown as
described (11). EGFR wild-type and knockout mouse
embryonic fibroblasts (MEF) were kindly provided by Z.
Dong (University of Minnesota, Minneapolis, MN).
Denoted constructs and si-RNAs were transfected into the
cells by using FuGENE6 and RNAiMax, respectively, as
described (11).
We characterized how EGF modulates the downstream
signaling pathway of oncogenic KITENIN in colorectal
cancer cells through cell cultures, immunoblotting and
immunoprecipitation, siRNA interference and RT-PCR
analyses, reporter and invasion assays, immunofluores-
cence, and immunohistochemistry.
Full methods are available at Clinical Cancer Research
Online.
Results
EGF induces synergic AP-1 activation and enhanced cell
motility in KITENIN-transfected cells, which does not
require EGFR or activated JNK
Previously, we found that transfection of KITENIN in
293 T cells causes a 3-fold increase in AP-1 activity, which
is mediated by interaction with Dvl/PKCd (11). However,
it is not fully understood how Dvl transduces down-
stream signals for AP-1 activation, although translocation
of Dvl to the plasma membrane is needed for JNK/AP-1
activation (18). To investigate whether extracellular sig-
nals also affect AP-1 activation in KITENIN-transfected
cells, we chose growth factors that positively regulate
colorectal cancer progression, such as EGF and HGF, as
candidate substances. In 293 T cells, treatment with EGF,
HGF, and FBS increased AP-1 activity (Fig. 1A). Interestin-
gly, significant increases in AP-1 activity were noted when
EGF, but notHGF or FBS, was given to KITENIN-transfected
Translational Relevance
EGFR-targeted therapy is an important approach in
colorectal cancer therapy; however, up to half of all
patients with colorectal cancer do not respond to this
therapy. Our present results indicate the presence of an
unconventional EGFR-independent signal of EGF, the
KAI1 C-terminal interacting tetraspanin (KITENIN)/
ErbB4–Dvl2–c-Jun axis, which mediates increased colo-
rectal cancer cell invasiveness and thereby enhances
tumor progression. Our results suggest that the KITE-
NIN/ErbB4–c-Jun axis could be a molecular basis for
conferring resistance to anti-EGFR agents in colorectal
cancer tissues in which KITENIN is highly expressed.
These findings support a rationale for combined target-
ing of the KITENIN complex to improve responses to
cetuximab-based therapy in EGFR/KITENIN-overexpres-
sing metastatic patients with colorectal cancer. We pro-
pose that, together with "quadruple negative" genotype
(tumors lacking alterations in KRAS, BRAF, PIK3CA, and
PTEN genes), lower KITENIN levels in resected tumor
tissues from metastatic patients with colorectal cancer
could be useful for identifying patients who would
benefit from EGFR-targeted therapies.
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cells compared with 293 T/parent cells, which suggests that
EGF specifically sensitized KITENIN-overexpressing cells
to exhibit synergistic promotion of AP-1 activity. However,
increases in AP-1 activity by EGF alone were attenuated by
KITENIN knockdown. In Caco2 colorectal cancer cells, cell
invasion (Fig. 1B) and anchorage-independent cell growth
(Fig. 1C) significantly increased after EGF treatment in
KITENIN-transfected Caco2 cells compared with Caco2/
parent cells.
The question thus arouse as to whether EGFR is involved
in the enhanced AP-1 activity and colorectal cancer cell
motility observed after EGF treatment under KITENIN
transfection. EGFR knockdown did not affect the elevation
in AP-1 activity by EGF in either KITENIN-transfected 293 T
cells (Supplementary Fig. S1A) or KITENIN-transfected
Caco2 cells (Fig. 2A, left), nor the elevated Caco2 cell
invasion by EGF treatment (Fig. 2A, right). Interestingly,
roughly the same level of phospho-ERK was observed
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Figure 1. EGF upregulates AP-1
and enhances cell motility in
KITENIN-transfected cells. A,
effect of growth factors on AP-1
activity under KITENIN
transfection. 293 T cells were
cotransfected with AP-1 reporter
with or without KITENIN or
following KITENIN siRNA and
treated with EGF (100 ng/mL), HGF
(40 ng/mL), or 10% FBS for 12
hours. Each bar representsmean
SEM for triplicate samples. si-scr,
nonspeciﬁc scrambled siRNA
(negative control). @, signiﬁcant
difference between groups
(@, P < 0.05). B, invasion assay in
Caco2 cells after EGF treatment.
Caco2/vector or Caco2 cells stably
transfected with KITENIN (Caco2/
KITENIN) were treated with EGF
(100 ng/mL) for 12 hours and
subjected to invasion assay. The
pictures shown represent three
independent experiments. The
histogram represents invading
cells, which were counted at the 5
chosen areas and represented as
bar graphs (mean  SEM, n ¼ 3).
The asterisk ( or @) indicates a
signiﬁcant difference between
groups (, P < 0.001;
@@, P < 0.01; @@@, P < 0.001).
C, cell growth assay in Caco2 cells
after EGF treatment. Caco2/vector
or Caco2/KITENIN cells were
subjected to anchorage-
independent cell growth assay.
EGF (100 ng/mL) was treated for 12
hours. The pictures shown
represent three independent
experiments. The areas of the
stained cells were measured and
represented as bar graphs
(mean  SEM, n ¼ 3).
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Figure 2. EGF exhibits synergic
AP-1 activation and enhanced
colorectal cancer cell motility
under elevatedKITENIN conditions
in an EGFR-independent manner.
A, effects of EGFR knockdown on
AP-1 synergy and onenhancedcell
invasion by EGF. Caco2/vector or
Caco2/KITENIN cells treated with
EGF for 12 hours were subjected to
AP-1 reporter (left) and invasion
(right) assays. NS, no signiﬁcant
difference between groups. B,
effects of chemical blockade of
EGFRon enhanced cell invasion by
EGF. Caco2/vector or Caco2/
KITENIN cells were treated with
EGF and/or AG1478 (1 mmol/L) for
12 hours. C–D, EGF action under
elevated KITENIN in MEF and SW-
620 cells that do not express
EGFR.C,EGFR-wild-type (top) and
EGFR-knockout (bottom) MEF
cells were transfected with
KITENIN and treatedwith EGF for 1
hour. D, SW-620/vector or SW-620
cells stably transfected with
KITENIN (SW-620/KITENIN) were
treated with EGF for 12 hours and
subjected to anchorage-
independent cell growth assay.
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between parent and KITENIN-transfected cells after EGF
treatment. Although increases in phospho-ERK by EGF treat-
ment were not affected by EGFR knockdown (Supplemen-
tary Fig. S1A and Fig. 2A), which can be explained by the
report thatmaximal EGF signaling can be achievedwith only
5% receptor occupancy (19), phospho-ERKdoesnot seem to
contribute to elevation of AP-1 activity by EGF under KITE-
NIN transfection. Moreover, chemical blockade of EGFR via
treatment of AG1478, an inhibitor of ErbB kinase activity
(20), or functional blockade of EGFR via treatment of cetux-
imab, an anti-EGFRmonoclonal antibody (4), did not affect
elevations inAP-1 activity (Supplementary Fig. S1B)or in cell
invasion (Fig. 2B and Supplementary Fig. S2) by EGF treat-
ment in KITENIN-transfected cells. Thus, phospho-EGFRdid
not seem to contribute to elevatedAP-1 activity byEGFunder
KITENIN transfection.
To elucidate whether EGF induces AP-1 activation under
KITENIN transfection in an EGFR-independentmanner, we
used EGFR-knockoutMEFs andEGFR-null colorectal cancer
cells. However, AP-1 activity was barely detected in EGFR-
knockout MEF cells and EGFR-null SW-620 cells, probably
because of differences in AP-1 reporter expression; thus,
c-Jun was examined following EGF treatment instead of
AP-1. As a positive control, c-Jun was increased following
EGF treatment in EGFR-wild-type (124% by densitometry;
Fig. 2C, top, 2nd column) but not in EGFR-knockout MEF
cells (100%; Fig. 2C, bottom, 2nd column). Also, greater
elevation of c-Jun was observed in KITENIN-transfected
EGFR-wild-type MEF cells after EGF treatment than in
empty vector–transfected cells (138% vs. 124%; Fig. 2C,
top). However, in EGFR-knockout MEF cells, c-Jun was
increased only in KITENIN-transfected cells following EGF
treatment (138% vs. 100%; Fig. 2C, bottom).
We further examined this EGF action by using SW-620
cells, an EGFR-null colorectal cancer cell line. Again, greater
elevation of c-Jun was observed after EGF treatment in
KITENIN-transfected SW-620 cells than in empty vector–
transfected cells (Fig. 2D, top). Compared with Caco2 and
HCT116 cells that expressed EGFR, SW-620 cells showed a
very low chemotactic response to fibronectin; however,
anchorage-independent cell growth increased after EGF
treatment in KITENIN-transfected SW-620 cells (Fig. 2D,
bottom). We interpreted these results to mean that EGF
induced elevated c-Jun/AP-1 activity and enhanced cell
motility in KITENIN-overexpressing colorectal cancer cells
in an EGFR-independent manner.
Next, we investigated whether enhanced AP-1 activity by
EGF under KITENIN transfection was derived from JNK
activity. In HCT116 cells, which express the highest level of
endogenous KITENIN among colorectal cancer cells (11),
there were no actual changes in phospho-JNK despite
increases in phospho-c-Jun following EGF treatment (Sup-
plementary Fig. S3A). Also, JNK blockade via pretreatment
with SP600125 did not influence the increased c-Jun level
by EGF in KITENIN-transfected 293 T cells (Supplementary
Fig. S3B). Therefore, EGF induces enhanced AP-1 activity/
cell motility under KITENIN expression, which does not
require EGFR kinase or activated JNK.
EGF induces AP-1 synergy via downregulation of
KITENIN-bound phospho-Dvl2 and subsequent
upregulation of c-Jun
Next, we investigated the underlying mechanism of
enhanced AP-1 activation (AP-1 synergy) by EGF under
KITENIN transfection. Because EGF induced AP-1 synergy
in an EGFR kinase- and EGFR-independent manner, the
downstream signaling pathways of EGFR, such as the PI3K-
mTOR and KRAS–RAF–MAPK pathways (5, 6), might be
ruled out as possible candidates. Our previous speculations
as to whether PMA acts as an upstream signal to the
functional KITENIN complex (in which KITNEIN induces
ERK/AP-1activationvia interactionwithDvls/PKCd; ref.11)
prompted us to assess whether PMA affects Dvls for AP-1
activation in KITENIN-overexpressing cells. PMA induced
5-fold increases in c-Jun, but concurrently reduced total
Dvl2 by 70% in KITENIN-transfected 293 T cells compared
with parent cells by densitometry (Fig. 3A), which suggested
that lowered endogenousDvl2 can result in increased c-Jun/
AP-1 activity. To explore the possibility of Dvl2 levels
contributing to increased c-Jun/AP-1 activity,wemodulated
Dvl2 levels in 293T cells to examineAP-1/TOPflash reporter
activity and c-Jun levels. Dvl2 knockdown increased AP-1
activity and c-Jun protein, while increasing Dvl2 resulted in
upregulation of TOPflash activity but not in AP-1 activity
(Supplementary Fig. S4A).
We then attempted to assesswhether EGF also increases c-
Jun-like PMA in colorectal cancer cells. HCT116 cells were
chosen and changes in Dvl2 were analyzed under phos-
phatase treatment because phospho-Dvl2–specific anti-
body was not available. At 2 hours after EGF treatment,
c-Junmarkedly increased to 3 times that before treatment by
densitometry, whereas phospho-Dvl2 and unphospho-
Dvl2 levels were reduced by half (Fig. 3B, top). EGF also
led to a reproducible 3-fold increase in c-Jun and a decrease
in total Dvl2 by 70% in KITENIN-transfected 293 T cells
compared with parent cells (Supplementary Fig. S4B). Also,
in KITENIN-transfected Caco2 cells, c-Jun increased by
120% and total Dvl2 decreased by 80% after EGF treatment
(Supplementary Fig. S4C). In addition, more increases in c-
Jun and lower levels of Dvl2 were observed after EGF
treatment in KITENIN-transfected EGFR-null MEF and
SW-620 cells, compared with those before treatment (Fig.
2C andD). To confirmwhether loweredDvl2 and increased
c-Jun were responsible for AP-1 synergy by EGF under
KITENIN transfection or by PMA, cotransfection of Dvl2
or a dominant negative c-Jun (DN-c-Jun) was undertaken.
Transfected Dvl2 or DN-c-Jun reversed the upregulated AP-
1 activity by EGF or PMA (Fig. 3C), indicating that down-
regulation of Dvl2 and upregulation of c-Jun is involved in
EGF-induced AP-1 synergy in KITENIN-overexpressed cells.
Next, we examined the characteristics of the interactions
between KITENIN and Dvl2 after EGF treatment. Only
phospho-Dvl2 interacted with KITENIN. Interactions
between KITENIN and Dvl2 disappeared after phosphatase
treatment (Fig. 3B, bottom). At 30 minutes after EGF treat-
ment in HCT116 cells, the level of KITENIN-bound phos-
pho-Dvl2 initially increased but decreased after 2 hours.
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Consistently, at 30minutes after EGF treatment in293T and
HCT116 cells, KITENIN translocation was observed from
the plasma membrane to cytoplasmic vesicles in which
phospho-Dvl2 was also localized (Fig. 3D, KITENIN
panels). Importantly, the number of colocalized vesicles
(cytoplasmic puncta) increased upon EGF treatment (Fig.
3D, merge panels), which indicated that membrane-asso-
ciated KITENIN is internalized and thereafter interacts with
phospho-Dvl2. Thus, we attempted to discern whether
decreases in phospho-Dvl2, rather than total Dvl2, are
responsible for increased c-Jun. When phosphorylation of
Dvl was blocked by treatment with D4476, a casein kinase I
inhibitor, phospho-c-Jun/total c-Jun was upregulated, but
not c-Fos (Fig. 3E, left). In contrast, cotransfection of casein
kinase I not only attenuated AP-1 synergy by EGF under
KITENIN transfection or by PMA, but also restored the
increased c-Jun and lowered total Dvl2 observed after EGF
treatment under KITENIN transfection or after PMA treat-
ment (Fig. 3E, right).We interpreted these results as follows:
EGF initially induces endocytosis of KITENIN and activates
the formation of a KITENIN/phospho-Dvl2 complex in
cytoplasmic vesicles. Thereafter, EGF downregulates KITE-
NIN-bound phospho-Dvl2, which subsequently contri-
butes to increased c-Jun/AP-1 activity.
Interestingly, Dvl2 knockdown did not increase tran-
scription of c-Jun and Dvl2 did not directly interact with
c-Jun (Supplementary Fig. S5A and S5B). JNK blocking also
did not affect EGF action in KITENIN-transfected cells
(Supplementary Fig. S3B). These data suggest that down-
regulation of phospho-Dvl2 after EGF treatment leads to
AP-1 synergy through stabilization of c-Jun protein.
Although, it is presently unknown how decreases in KITE-
NIN-bound phospho-Dvl2 stabilize c-Jun, this mechanism
is distinct from the known regulators of phospho-c-Jun,
such as N-terminal phosphorylation of c-Jun by JNK or the
MEK/RACO-1 pathway (21, 22).
ErbB4 is required for EGF-induced AP-1 synergy
Because we found that EGFR is not necessary for EGF-
induced AP-1 synergy and that downregulation of KITE-
NIN-bound phospho-Dvl2 is responsible for this EGF
action, we attempted to address whether KITENIN may
recruit other receptor tyrosine kinases (RTK) as coregulators
to assist in the processing of KITENIN-bound Dvl2. To
examine whether expression levels of KITENIN may affect
the activation of RTK, we compared the phosphorylation
levels of various RTKs between parent and KITENIN-over-
expressing colorectal cancer cells and between parent
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Figure 3. EGF induces increased interactions of KITENIN with Dvl2 in cytoplasmic vesicles, as well as downregulation of KITENIN-bound phospho-Dvl2
and upregulation of c-Jun. A, effect of PMA on c-Jun and Dvl2 in KITENIN-transfected cells. Immunoreactive Dvl2/c-Jun was examined after PMA
(100 nmol/L) treatment for 4 hours in 293 T cells transfected with or without KITENIN andmeasured by densitometry in triplicate experiments. Phospho-Dvl2
was detected by phosphorylation-dependent mobility shift with Dvl2-speciﬁc antibody. The arrow and arrowhead indicate phospho- and unphospho-Dvl2,
respectively. B, effects of EGF on c-Jun and Dvl2 (top) and on KITENIN-bound phospho-Dvl2 (bottom) in colorectal cancer cells. Serum-starved
HCT116 cells were treated with EGF at the time points indicated. Total cell lysates (500 mg) were treated with or without lambda phosphatase (lPpase) and
were analyzed by immunoblot (top) or immunoprecipitation (bottom). The arrow and arrowhead indicate phospho- and unphospho-Dvl2, respectively;
the upper band disappeared after phosphatase treatment. C, effects of transfection with Dvl2 or DN-c-Jun on EGF-induced AP-1 synergy under
elevated KITENIN conditions. 293 T cells were cotransfected with AP-1 reporter with or without KITENIN and with Dvl2 or DN-c-Jun, and treated
with EGF or PMA (20 nmol/L) for 12 hours. (Continued on the following page.)
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and KITENIN-knockdown colorectal cancer cells. In KITE-
NIN-overexpressing Caco2 cells, phospho-RTKs, including
ErbB4 andRON,were increased,whereas phospho-Ephrin1
was decreased. Meanwhile, phospho-ErbB4, phospho-
RON, and phospho-c-Ret were decreased in KITENIN-
knockdownHCT116 cells (Supplementary Fig. S6A). Phos-
pho-c-Met was detected constantly in HCT116 cells. Thus,
among the phospho-RTKs studied, RON and ErbB4 were
consistently identified as being affected by KITENIN. As
expected, phospho-ErbB4 and phospho-RON, but not their
total forms, were increased in Caco2/KITENIN cells and
decreased in HCT116/si-KITENIN cells (Supplementary
Fig. S6B). Interestingly, enhanced invasion of Caco2/KITE-
NIN cells, comparedwith parent cells, indicative of a gain of
function, was restored by ErbB4 knockdown, but not by
RON knockdown (Fig. 4A). These results showed ErbB4 to
be an essential cofactor in KITENIN signaling, enhancing
colorectal cancer cell invasion.
Subsequent to the above, we next attempted to uncover
whether ErbB4 is required as a binding partner to assist in
KITENIN signaling.We found that KITENIN interactedwith
the ErbB4 via its C-terminal cytoplasmic domain (Supple-
mentary Fig. S6C) and that interaction between KITENIN
and ErbB4 increased upon EGF treatment (Fig. 4B).
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Figure 3. (Continued. ) D, effect of
EGF on colocalization of KITENIN
with Dvl2 in the cytoplasmic
vesicles. 293 T cells (top) were
transiently transfected with Dvl2-
GFP and KITENIN-HA constructs
and HCT116 cells (bottom) were
transiently transfected with Dvl2-
GFP for 36 hours. Cells were
visualized by ﬂuorescent confocal
microscope after EGF treatment
for 30 minutes. Representative
examples are shown; the yellow
color in themerged panel indicates
colocalization of Dvl2 with
KITENIN. E, effects of modulating
Dvl2 phosphorylation on c-Jun
(left) and on AP-1 synergy by EGF
(right). 293 T cells were treatedwith
the casein kinase I inhibitor D4476
(100 mmol/L) for 4 hours to block
Dvl-phosphorylation, after which
Dvl2, c-Jun, and c-Fos levels were
examined (left). Next, cells were
cotransfected with AP-1 reporter
with or without KITENIN and
with casein kinase Ie, and
subsequently treated with EGF
or PMA (20 nmol/L) for 12 hours
(right).
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Importantly, ErbB4 knockdown attenuated EGF-induced
AP-1 synergy in KITENIN-transfected cells (Fig. 4C), indi-
cating that ErbB4 is required for EGF-induced AP-1 synergy.
Moreover, EGF treatment induced significant increases in
AP-1 activity in KITENIN/ErbB4-cotransfected cells, com-
pared with cells transfected with EGFR alone, ErbB4 alone,
or KITENIN/EGFR (Supplementary Fig. S7). Consistently,
ErbB4 knockdown decreased interactions between KITE-
NIN and Dvl2 (Fig. 4D, top), and reversed EGF-induced
increases in c-Jun and decreases in Dvl2, which were not
affected by EGFR knockdown (Fig. 4D, bottom). Thus, we
discerned ErbB4 to be necessary in elevating KITENIN-Dvl2
interactions after EGF treatment and assisting in the proces-
sing of KITENIN-boundDvl2, and thereby to be responsible
for increased c-Jun after EGF treatment under KITENIN
transfection. Also, EGF stimulated the formation of KITE-
NIN/ErbB4 complexes.
The EGF-KITENIN/ErbB4–c-Jun axis upregulates
colorectal cancer cell invasion
We finally examined whether the delineated EGF-KITE-
NIN/ErbB4–c-Jun axis works in an EGFR-independent/
ErbB4-dependent fashion by using CHO cells, a known all
ErbB-null cell line. In KITENIN/ErbB4-cotransfected CHO
cells, more increases in c-Jun and decreases in Dvl2
were observed following EGF treatment than in parent or
KITENIN alone–transfected cells (Fig. 5A). This further
confirmed that the KITENIN/ErbB4-mediated downstream
signal of EGF increases c-Jun in an EGFR-independent
manner. Moreover, our observations that c-Jun increases
following EGF treatment in both KITENIN-transfected
EGFR-knockout cells (Fig. 2C) and EGFR-null SW-620 cells
(Fig. 2D) and that roughly the same AP-1 activity was
observed following EGF treatment between KITENIN/
EGFR-cotransfected cells and EGFR alone–transfected cells
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Figure 4. ErbB4 is necessary for
AP-1 synergy by EGF under
elevated KITENIN conditions.
A, effects of RON- or ErbB4-
knockdown on increased cell
invasion by KITENIN. Caco2/
vector or Caco2/KITENIN cells
were transfected with si-scr, si-
RON, or si-ErbB4 for 48 hours and
subjected to invasion assay. B,
EGF increased interactions of
KITENIN with ErbB4. Caco2/
KITENIN cells were treated
with EGF for 12 hours, and
immunoreactive KITENIN and
ErbB4 were examined after
immunoprecipitation with anti-
ErbB4 antibody. C, ErbB4 is
necessary for EGF-KITENIN-AP-1
signaling. 293 T cells were
cotransfected with KITENIN and
AP-1 reporter with or without
ErbB4-siRNA treatment and
subsequently treated with EGF for
12 hours. D, ErbB4-knockdown
decreased the interactions of
KITENIN with Dvl2 (top) and
restored the EGF action under
elevated KITENIN conditions
(bottom). Caco2/KITENIN cells
were transfected with Dvl2 and
treated with ErbB4-siRNA for 36
hours. Immunoreactive Dvl2 or
KITENIN was examined after
immunoprecipitation with anti-
KITENIN or anti-Dvl2 antibody,
respectively (top). Caco2/KITENIN
cells were treated with ErbB1-
siRNA or ErbB4-siRNA for 36
hours. Immunoreactive Dvl2 and
c-Jun were examined after EGF
treatment (bottom).
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(Supplementary Fig. S7) indicated that the axis of EGF-
KITENIN/ErbB4–c-Junmight not be regulated by asymmet-
ric EGFR-ErbB4 heterodimer formation.
We next investigated whether coexpression of ErbB4/
KITENIN led to further increased colorectal cancer cell
invasion as a result of strengthening the EGF-KITENIN/
ErbB4–c-Jun axis. To do so, we chose HCT116 cells, which
have the highest endogenous KITENIN levels and also
harbor a KRAS mutation. Cell invasion was markedly
increased in ErbB4-transfected HCT116 cells following
EGF treatment compared with HCT116/parent cells
(Fig. 5B). However, this elevation pattern was abolished
after KITENIN knockdown, although HCT116 cells still
expressed elevated ErbB4. Thus, KITENIN may be a more
important component than ErbB4 in regulating colorectal
cancer cell invasiveness via the EGF-KITENIN/ErbB4–c-
Jun axis. Also, treatment of AG1478 in KITENIN/ErbB4-
cotransfected Caco2 cells did not attenuate the action of
EGF on the increased cell invasion (Fig. 5C), as in KITE-
NIN-transfected Caco2 cells (Fig. 2B). This confirmed that
the upregulation of cell invasiveness by EGF under coex-
pressed KITENIN/ErbB4 does not require modulation of
ErbB kinase activity.
Higher levels of KITENIN/ErbB4 are coexpressed in
tumor tissues from patients with metastatic colorectal
cancer who show poor responses to cetuximab/
chemotherapy
The use of an anti-EGFR monoclonal antibody has
been implemented as the only effective tool in clinical
practice for treating patients with metastatic colorectal
cancer since 2004, but objective response rates even for
those of KRAS wild-type status are below 20% (5–7).
Accordingly, we attempted to elucidate the functional
significance of the KITENIN/ErbB4 complex outlined in
this study in cetuximab-resistant patients with metastatic
colorectal cancer. To do so, we examined the expression
levels of KITENIN and ErbB4 in resected tumor tissues
obtained from patients with metastatic colorectal cancer
before treatment. These patients exhibited wild-type
KRAS and were primarily treated with cetuximab/chemo-
therapy (Supplementary Table S1). The immunohisto-
chemical coexpression of KITENIN/ErbB4 was great in
tumor tissues from patients with metastatic colorectal
cancer who showed progression of disease (PD) at initial
stages (2 months) after treatment with cetuximab, com-
pared with those who exhibited a partial response (PR).
However, the expression level of ErbB4 in patients with
colorectal cancer who showed a PR was not matched with
that of KITENIN (Fig. 6A).
To assess quantitatively the immunohistochemical
expression of KITENIN and ErbB4 in colon tissues, a score
was calculated by using the intensity of the staining and
the size of the positively stained area. The KITENIN expres-
sion score was significantly greater in tumor tissues from
patients who showed PD than in those who exhibited a PR
(Fig. 6B; 8.05 0.30, n¼ 22 vs. 4.42 0.33, n¼ 33; P¼ 5.9
 1010). ErbB4was highly expressed in tumor tissues from
both groups, with no significant difference in ErbB4
scores (Fig. 6B; 6.05  0.51, n ¼ 22 vs. 6.18  0.41, n ¼
33; P ¼ 0.84). Patients showing good early response had a
significantly longer progression-free survival (PFS) than
patients with poor response (Supplementary Table S1,
P ¼ 0.014). Thus, our data suggest that early chemoresis-
tance to cetuximab in patients highly expressing KITENIN
may originate from the existence of an unconventional EGF
signal, which is switched on under the elevated KITENIN
condition.
KITENIN/ErbB4–c-Jun axis confers resistance to
cetuximab in colorectal cancer cells inwhichKITENIN is
highly expressed
The novel EGF signal described here may endow colo-
rectal cancer cells expressing higher KITENIN with
enhanced survival in response to EGFR-targeted thera-
pies. To test this possibility, we first examined the sus-
ceptibility of various colorectal cancer cells to increasing
doses of cetuximab. We found that HCT116 and Caco2
cells expressing higher levels of endogenous KITENIN
were more resistant to cetuximab than were DLD1 and
SW620 cells expressing lower KITENIN (Supplementary
Fig. S8A). To examine whether the expression levels of
KITENIN affected the survival of colorectal cancer cells in
response to cetuximab, we first chose Caco2 colorectal
cancer cells, a KRAS/BRAF wild-type cell line (23), as
these would be suitable models for the clinical setting
where EGFR-targeted therapy is used (5, 6). Although
there was no difference in survival to cetuximab between
empty vector– and KITENIN-transfected Caco2 cells,
highly KITENIN-expressing Caco2 cells were resistant to
cetuximab, whereas KITENIN-knockdown Caco2 cells
showed increased sensitivity (Supplementary Fig. S8B).
We also compared the proliferation rate to cetuximab in
colorectal cancer cells with mutant KRAS/BRAF, such as
DLD1 and HCT116 cells. We found that highly KITENIN-
expressing DLD1 cells were resistant to cetuximab, where-
as KITENIN-knockdown HCT116 cells showed sensitivity
to cetuximab (Supplementary Fig. S8C). Thus, these
results indicated that KITENIN/ErbB4–c-Jun axis confers
resistance to cetuximab in Caco2 cells with KRAS/BRAF
wild type in which KITENIN is highly expressed. Also, our
results suggest that this axis can contribute to the early
acquisition of resistance to cetuximab in colorectal cancer
cells with mutant KRAS/BRAF.
Discussion
Among the ligands known to interact with EGFR, TGFa
exhibits an EGFR-independent action, in which it protects
Naked2 from proteasomal degradation (24). However,
EGFR-independent actions for EGF have not yet been
explored. In this study, we found a novel EGFR-indepen-
dent action for EGF that works under elevated expression of
KITENIN/ErbB4: EGF stimulates the formation of KITE-
NIN/ErbB4 complexes that target phospho-Dvl2 for degra-
dation, which then leads to the upregulation of c-Jun and
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colorectal cancer cell motility (Fig. 5D). Although the
detailed mechanisms of what exactly EGF binds to, how
ErbB4 assists in processingKITENIN-boundphospho-Dvl2,
and how lowered phospho-Dvl2 within the KITENIN/
ErbB4 complex stabilizes c-Jun are unknown, the down-
stream signal of EGF, the KITENIN/ErbB4-Dvl2-c-Jun path-
way, that we identified in this study differs from the previ-
ously reported downstream pathways of EGF that require
binding to EGFR (3–6). Thus, we have identified a new
EGFR-independent promotility signal of EGF in colorectal
cancer cells.
The lack of response to anti-EGFR agents in "quadru-
ple-negative" patients may be because of multiple rea-
sons, including the oncogenic deregulation of the same 4
genes by mechanisms other than mutations, providing an
alternate pathway of survival and proliferation (5, 6, 25).
As for the new molecular determinants of resistance to
anti-EGFR agents, proto-oncogene securin promotes
resistance to gefitinib-induced apoptosis via an EGFR-
independent pathway in human cancer cells (26) and
TGFb provides an intrinsic EGFR-independent survival
signal that protects squamous cancer cells from cetuxi-
mab-dependent cellular cytotoxicity (27). In this study,
we observed that KITENIN was significantly highly
expressed in tumor tissues from metastatic colorectal
cancer patients with wild-type KRAS who showed poor
responses to cetuximab/conventional chemotherapy after
the initial stages of treatment. Furthermore, this novel
downstream signal of EGF endowed colorectal cancer
cells expressing higher KITENIN with enhanced survival
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Figure 5. EGF-KITENIN/ErbB4-c-
Jun axis upregulates colorectal
cancer cell invasion. A, EGF-
KITENIN/ErbB4-c-Jun axis works
in CHO cells. CHO-K1 cells were
cotransfectedwith KITENINwith or
without ErbB4 JM-a/CYT-2 (a2) for
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C, effects of ErbBkinaseblocker on
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to cetuximab. Therefore, we suggest that the KITENIN/
ErbB4–c-Jun axis could be a molecular basis for confer-
ring resistance to anti-EGFR agents in colorectal cancer
tissues in which KITENIN is highly expressed.
c-Jun belongs to the dimeric AP-1 family of transcription
factors, which are critical regulators of the gene expression
that defines the invasive phenotype of cancer (28).
Phospho-c-Jun interacts with TCF4 to form a c-Jun–
TCF4–b-catenin complex that enhances intestinal tumori-
genesis, whereas deletion of c-Jun in intestinal tissue reduces
APCmin/þ-mediated tumor formation (29). Thus, elevated c-
Jun resulting from the EGF-driven KITENIN/ErbB4–Dvl2–
c-Jun axis may enhance colorectal tumor progression by
increasing colorectal cancer cell invasiveness. Currently, the
upstreammechanism that regulates the phosphorylation of
c-Jun is largely unknown (30, 31), yet we present evidence
of a possiblemechanism for the stabilizing of c-Jun through
the degradation of phospho-Dvl2 within the functional
KITENIN/ErbB4 complex.
Gene amplification or overexpression is a common
mechanism of RTK deregulation in many cancers that not
only yields increased surface abundance and signaling, but
that is also likely to alter the distribution, clustering, and
dimeric partnering of RTKs (32). Structural and other stud-
ies have indicated that many RTKs form dimers and higher-
order oligomers in the absence of ligand, which suggests
more sophisticated mechanisms of ErbB partnering, acti-
vation, and ligand-independent clustering (33, 34). Our
present results suggest that overexpressed KITENIN alters
the complex equilibrium of ErbB4-containing clustering to
form a KITENIN/ErbB4 complex, which consequently
increases c-Jun signaling output in an EGFR-independent
manner. Although the underlying mechanism is unknown,
this is thought to occur via physical collaboration between
KITENIN and ErbB4.
Recently, the emergence of KRAS mutations and ampli-
fication was shown to be associated with primary and
acquired resistance to cetuximab or panitumumab (5,
6, 25, 35, 36). Previously, we observed that the functional
KITENIN complex is indispensable for invasion of DLD1
and HCT116 cells harboring KRAS mutation (11), indi-
cating that the KITENIN complex is also required as a
downstream effector for increased invasiveness by KRAS.
We here found that highly KITENIN-expressing DLD1
and HCT116 cells were also more resistant to acute
exposure of cetuximab. It thus suggests that blockers of
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the KITENIN complex may be effective in patients with
colorectal cancer with KRAS mutation who exhibit poor
responses to anti-EGFR agents. Therefore, other than the
EGFR pathway, our results support the rationale for
combined targeting of the KITENIN complex to improve
responses to cetuximab-based therapy in EGFR/KITENIN-
overexpressing patients with metastatic colorectal cancer.
Such a strategy is expected to lower resistance to ErbB
inhibitors in patients with metastatic colorectal cancer,
regardless of KRAS status.
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Figure 6. Higher levels of KITENIN/
ErbB4 are coexpressed in tumor
tissues from metastatic patients
with colorectal cancer with poor
responses to treatment with
cetuximab. A, KITENIN and
ErbB4 expression by
immunohistochemistry (dark
brown color) in serially sectioned
colon tissues from patients with
metastatic colorectal cancer with
wild-typeKRASwhowere primarily
treated with cetuximab.
Representative examples are
shown: #1, #2, and #3 are derived
from patients with stage IV
colorectal cancerwhoexhibitedPR
at 2 months after treatment with
cetuximab; #4 and #5 are from
patients who showed PD over the
same period. Scale bar: 50 mm.
B, positive correlation between the
expression score of KITENIN and
poor responses to cetuximab at
initial stages after treatment. To
assess the immunohistochemical
level of KITENIN and ErbB4, a
score was calculated and the
signiﬁcance thereof between the
PR and PD groups was tested as
described in the Materials and
Methods. NS, not signiﬁcant.
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